The Need for High Radiation Doses (≥70 Gy) Even in Early Postoperative Irradiation After Radical Prostatectomy. A Mono-Institutional Analysis on 334 High-Risk, Node-Negative PatientsPage 966
C. Cozzarini, F. Montorsi, C. Fiorino, F. Alongi, A. Bolognesi, L. Filippo Da Pozzo, G. Guazzoni, M. Freschi, M. Roscigno, V. Scattoni, P. Rigatti, and N. Di Muzio
“The end-point of this study was to assess whether early adjuvant RT (EART) doses ≥70 Gy after radical prostatectomy significantly improved the clinical outcome of high-risk, node-negative, patients. After a median follow-up of 9 years, both 5-year biochemical relapse-free (bRFS) and disease-free survival (DFS) were significantly higher in patients receiving EART dose ≥70.2 Gy. In the hormono-naïve cases, the impact of high-dose EART on bRFS and DFS was maintained only for those with undetectable PSA values, possibly owing to extrapelvic micrometastatic disease. This series supports an elegant radiobiological model postulating a 3% proportional gain of 5-year bRFS per incremental Gray in the postoperative setting.”
Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV StatusPage 1053
C. Fallai, F. Perrone, L. Licitra, S. Pilotti, L. Locati, P. Bossi, E. Orlandi, M. Palazzi, and P. Olmi
“This paper is on the prognostic value of the TP53 mutation and human papilloma virus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC) patients treated with radiotherapy or radiochemotherapy. The HPV+ patients had significantly better survival than HPV-, showed neither distant metastases nor second tumors. In HPV- patients, no survival difference was observed between the groups with or without TP53 mutation. While HPV+ patients respond very well to radiochemotherapy, new treatment tools should be explored in HPV- patients. This paper supports the idea that OPSCC is not a homogeneous entity, and that HPV- and HPV+ cases should be considered separately.”
Radioactive EGFR Antibody Cetuximab in Multimodal Cancer Treatment: Stability and Synergistic Effects with RadiotherapyPage 1226
D. Rades, C. Wolff, R. Nadrowitz, C. Breunig, S. E. Schild, M. Baehre, and B. Meller
“This preclinical study is on radiolabeled cetuximab (131I-Erbi), an epidermal growth factor receptor (EGFR) antibody. In this study, 131I-Erbi was stable for 72 hours, which is long enough to allow the antibody to cross the blood brain barrier and accumulate in brain metastases. This result is a prerequisite for a planned in vivo study of WBRT plus cetuximab in patients with brain metastases from non-small cell lung cancer. Furthermore, it was demonstrated that radiotherapy leads to an increased tumor cell uptake of 131I-Erbi, and that radiotherapy and 131I-Erbi synergistically inhibit tumor cell proliferation.”
Non-Random Intra-fraction Target Motions and General Strategy of Correction for Spine Stereotactic Body RadiotherapyPage 1261
L. Ma, A. Sahgal, S. Hossain, C. Chuang, M. Descovich, K. Huang, A. Gottschalk, and D. A. Larson
“This study found that spine tumors undergo small but unexpectedly complex positional changes during stereotactic body radiosurgery treatment, including sagging and twisting. These positional changes are location-dependent within the spine. Managing such changes is important because spine treatments demand high precision and often long treatment times. The authors analyzed hundreds of clinical treatment sessions and found that intra-fractional periodic imaging and six degrees-of-freedom corrections made approximately every 5 minutes are sufficient to account for and correct complex target motions to ensure accurate dose deposition within 1 mm and 1 degree.”
FULL TEXT
Page 966